#BEGIN_DRUGCARD DB01921

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C5H10N2O4

# Chemical_IUPAC_Name:
(2Z,3S,4S,5R)-2-(hydroxyimino)piperidine-3,4,5-triol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Xylose-Derived Lactam Oxime

# HET_ID:
LOX

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C5H10N2O4/c8-2-1-6-5(7-11)4(10)3(2)9/h2-4,8-11H,1H2,(H,6,7)/t2-,3+,4-/m1/s1

# InChI_Key:
InChIKey=JDBSITHMKSTORG-FLRLBIABSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1921

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
162.1439

# Molecular_Weight_Mono:
162.064056818

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1FH9

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.4

# Predicted_LogS:
-0.33

# Predicted_Water_Solubility:
7.67e+01 g/l

# Primary_Accession_No:
DB01921

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
445614

# PubChem_Substance_ID:
46508648

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02054

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O\N=C1/NC[C@@H](O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:37 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M15824

# Drug_Target_1_GenBank_ID_Protein:
144425

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
cex

# Drug_Target_1_Gene_Sequence:
>1455 bp
ATGCCTAGGACCACGCCCGCACCCGGCCACCCGGCCCGCGGCGCCCGCACCGCTCTGCGC
ACGACGCGCCGCCGCGCGGCGACGCTCGTCGTCGGCGCCACGGTCGTGCTGCCCGCCCAG
GCCGCGACCACGCTCAAGGAGGCCGCCGACGGCGCCGGCCGGGACTTCGGCTTCGCGCTC
GACCCCAACCGGCTCTCGGAGGCGCAGTACAAGGCGATCGCCGACAGCGAGTTCAACCTC
GTCGTCGCCGAGAACGCGATGAAGTGGGACGCCACCGAGCCCTCGCAGAACAGCTTCTCC
TTCGGCGCGGGCGACCGCGTCGCGAGCTACGCCGCCGACACCGGCAAGGAGCTGTACGGC
CACACGCTCGTCTGGCACTCGCAGCTGCCCGACTGGGCGAAGAACCTCAACGGCTCCGCG
TTCGAGAGCGCGATGGTCAACCACGTGACGAAGGTCGCCGACCACTTCGAGGGCAAGGTC
GCGTCGTGGGACGTCGTCAACGAGGCGTTCGCCGACGGCGACGGCCCGCCGCAGGACTCG
GCGTTCCAGCAGAAGCTCGGCAACGGCTACATCGAGACCGCGTTCCGGGCGGCACGTGCG
GCGGACCCGACCGCCAAGCTGTGCATCAACGACTACAACGTCGAGGGCATCAACGCGAAG
AGCAACTCGCTCTACGACCTCGTCAAGGACTTCAAGGCGCGCGGCGTCCCGCTCGACTGC
GTCGGGTTCCAGTCGCACCTCATCGTCGGCCAGGTGCCGGGCGACTTCCGGCAGAACCTG
CAGCGGTTCGCGGACCTGGGCGTGGACGTGCGCATCACCGAGCTCGACATCCGCATGCGG
ACGCCCTCCGACGCGACCAAGCTCGCGACCCAGGCGGCCGACTACAAGAAGGTCGTGCAG
GCCTGCATGCAGGTGACCCGCTGCCAGGGCGTGACCGTCTGGGGCATCACCGACAAGTAC
TCGTGGGTGCCGGACGTCTTCCCGGGCGAGGGGGCCGCGCTGGTGTGGGACGCGAGCTAC
GCCAAGAAGCCGGCCTACGCCGCCGTGATGGAGGCCTTCGGCGCGAGCCCGACGCCGACG
CCCACCACGCCGACCCCGACGCCCACGACGCCGACGCCGACCCCGACGTCCGGTCCGGCC
GGGTGCCAGGTGCTGTGGGGCGTCAACCAGTGGAACACCGGCTTCACCGCGAACGTCACC
GTGAAGAACACGTCCTCCGCTCCGGTCGACGGCTGGACGCTCACGTTCAGCTTCCCGTCC
GGCCAGCAGGTCACCCAGGCGTGGAGCTCGACGGTCACGCAGTCCGGCTCGGCCGTGACG
GTCCGCAACGCCCCGTGGAACGGCTCGATCCCGGCGGGCGGCACCGCGCAGTTCGGCTTC
AACGGCTCGCACACGGGCACCAACGCCGCGCCGACGGCGTTCTCGCTCAACGGCACGCCC
TGCACGGTCGGCTGA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
1678739	Tull D, Withers SG, Gilkes NR, Kilburn DG, Warren RA, Aebersold R: Glutamic acid 274 is the nucleophile in the active site of a "retaining" exoglucanase from Cellulomonas fimi. J Biol Chem. 1991 Aug 25;266(24):15621-5.
1761039	Gilkes NR, Claeyssens M, Aebersold R, Henrissat B, Meinke A, Morrison HD, Kilburn DG, Warren RA, Miller RC Jr: Structural and functional relationships in two families of beta-1,4-glycanases. Eur J Biochem. 1991 Dec 5;202(2):367-77.
3096818	O'Neill G, Goh SH, Warren RA, Kilburn DG, Miller RC Jr: Structure of the gene encoding the exoglucanase of Cellulomonas fimi. Gene. 1986;44(2-3):325-30.
7766609	Xu GY, Ong E, Gilkes NR, Kilburn DG, Muhandiram DR, Harris-Brandts M, Carver JP, Kay LE, Harvey TS: Solution structure of a cellulose-binding domain from Cellulomonas fimi by nuclear magnetic resonance spectroscopy. Biochemistry. 1995 May 30;34(21):6993-7009.
7910761	MacLeod AM, Lindhorst T, Withers SG, Warren RA: The acid/base catalyst in the exoglucanase/xylanase from Cellulomonas fimi is glutamic acid 127: evidence from detailed kinetic studies of mutants. Biochemistry. 1994 May 24;33(20):6371-6.
7918478	White A, Withers SG, Gilkes NR, Rose DR: Crystal structure of the catalytic domain of the beta-1,4-glycanase cex from Cellulomonas fimi. Biochemistry. 1994 Oct 25;33(42):12546-52.
8564541	White A, Tull D, Johns K, Withers SG, Rose DR: Crystallographic observation of a covalent catalytic intermediate in a beta-glycosidase. Nat Struct Biol. 1996 Feb;3(2):149-54.
9537990	Notenboom V, Birsan C, Warren RA, Withers SG, Rose DR: Exploring the cellulose/xylan specificity of the beta-1,4-glycanase cex from Cellulomonas fimi through crystallography and mutation. Biochemistry. 1998 Apr 7;37(14):4751-8.
9731776	Notenboom V, Birsan C, Nitz M, Rose DR, Warren RA, Withers SG: Insights into transition state stabilization of the beta-1,4-glycosidase Cex by covalent intermediate accumulation in active site mutants. Nat Struct Biol. 1998 Sep;5(9):812-8.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2448

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
51291

# Drug_Target_1_Name:
Exoglucanase/xylanase [Includes: Exoglucanase

# Drug_Target_1_Number_of_Residues:
484

# Drug_Target_1_PDB_ID:
1J01

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00331	Glyco_hydro_10
PF00553	CBM_2

# Drug_Target_1_Protein_Sequence:
>Exoglucanase/xylanase precursor [Includes: Exoglucanase
MPRTTPAPGHPARGARTALRTTRRRAATLVVGATVVLPAQAATTLKEAADGAGRDFGFAL
DPNRLSEAQYKAIADSEFNLVVAENAMKWDATEPSQNSFSFGAGDRVASYAADTGKELYG
HTLVWHSQLPDWAKNLNGSAFESAMVNHVTKVADHFEGKVASWDVVNEAFADGDGPPQDS
AFQQKLGNGYIETAFRAARAADPTAKLCINDYNVEGINAKSNSLYDLVKDFKARGVPLDC
VGFQSHLIVGQVPGDFRQNLQRFADLGVDVRITELDIRMRTPSDATKLATQAADYKKVVQ
ACMQVTRCQGVTVWGITDKYSWVPDVFPGEGAALVWDASYAKKPAYAAVMEAFGASPTPT
PTTPTPTPTTPTPTPTSGPAGCQVLWGVNQWNTGFTANVTVKNTSSAPVDGWTLTFSFPS
GQQVTQAWSSTVTQSGSAVTVRNAPWNGSIPAGGTAQFGFNGSHTGTNAAPTAFSLNGTP
CTVG

# Drug_Target_1_Reaction:
Endohydrolysis of 1,4-beta-D-xylosidic linkages in xylans REFERENCE 1 [PMID:14403433] AUTHORS HOWARD BH, JONES G, PURDOM MR. TITLE The pentosanases of some rumen bacteria. JOURNAL Biochem. J. 74 (1960) 173-80. ORGANISM Triticum aestivum [GN:etae]

# Drug_Target_1_Signals:
1-41

# Drug_Target_1_Specific_Function:
The biological conversion of cellulose to glucose generally requires three types of hydrolytic enzymes:(1) Endoglucanases which cut internal beta-1,4-glucosidic bonds; (2) Exocellobiohydrolases that cut the dissaccharide cellobiose from the nonreducing end of the cellulose polymer chain; (3) Beta-1,4- glucosidases which hydrolyze the cellobiose and other short cello- oligosaccharides to glucose

# Drug_Target_1_SwissProt_ID:
P07986

# Drug_Target_1_SwissProt_Name:
GUX_CELFI

# Drug_Target_1_Synonyms:
1,4-beta-cellobiohydrolase
Beta-1,4- glycanase CEX
EC 3.2.1.8
EC 3.2.1.91
Endo-1,4-beta-xylanase B
Exocellobiohydrolase
Exoglucanase/xylanase

# Drug_Target_1_Theoretical_pI:
6.62

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01921
